NasdaqGM:GPCRPharmaceuticals
How Phase 2b Oral GLP-1 Data and Phase 3 Plans Will Impact Structure Therapeutics (GPCR) Investors
Structure Therapeutics recently published Phase 2b ACCESS trial results for its oral GLP-1 agonist aleniglipron in Nature Medicine and presented the data at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant weight loss and improvements in multiple cardiovascular risk markers in people with obesity or overweight.
An interesting insight from the open-label extension is that many participants who interrupted dosing could restart or up-titrate...